French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products. The report highlights the safety and effectiveness of INTERCEPT platelets during the first full year of routine use.“The new hemovigilance data published by ANSM underscores the clinical utility and the safety benefits conferred by the use of the INTERCEPT Blood Systems for platelets,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “We are proud that every single patient receiving a platelet transfusion in France today is benefitting from our pathogen-reduction technology.”Key highlights from the report include:320,613 units of platelets were transfused in France and its territories during 2018, of which 320,235 (99.9%) were INTERCEPT treatedZero cases of bacterial infec
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus Corporation Announces First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Cerus GAAP EPS of -$0.05 in-line, revenue of $43.4M beats by $5.05M [Seeking Alpha]Seeking Alpha
- Cerus Corporation Announces First Quarter 2024 Financial ResultsBusiness Wire
- ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024Business Wire
CERS
Earnings
- 5/2/24 - Miss
CERS
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/26/24 - Form DEFA14A
- CERS's page on the SEC website